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Michael Boyd,a Paul Shabram,b Qian Ruan,b Mayank Patel,b Dan H. Baroucha,c
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USAa; PaxVax, San Diego, California, USAb; Ragon Institute of
MGH, MIT, and Harvard, Boston, Massachusetts, USAc
Replication-competent adenovirus (rcAd)-based vaccine vectors may theoretically provide immunological advantages over rep-
lication-incompetent Ad vectors, but they also raise additional potential clinical and regulatory issues. We produced replication-
competent Ad serotype 26 (rcAd26) vectors by adding the E1 region back into a replication-incompetent Ad26 vector backbone
with the E3 or E3/E4 regions deleted. We assessed the effect of vectorization on the replicative capacity of the rcAd26 vaccines.
Attenuation occurred in a stepwise fashion, with E3 deletion, E4 deletion, and human immunodeficiency virus type 1 (HIV-1)
envelope (Env) gene insertion all contributing to reduced replicative capacity compared to that with the wild-type Ad26 vector.
The rcAd26 vector with E3 and E4 deleted and containing the Env transgene exhibited 2.7- to 4.4-log-lower replicative capacity
than that of the wild-type Ad26 in vitro. This rcAd26 vector is currently being evaluated in a phase 1 clinical trial. Attenuation as
a result of vectorization and transgene insertion has implications for the clinical development of replication-competent vaccine
vectors.
The development of a safe and effective human immunodefi-ciency virus type 1 (HIV-1) vaccine is an urgent global health
priority. An HIV-1 vaccine should be simple to administer, be
long acting, and provide protection against mucosal HIV-1 expo-
sure. Replication-incompetent adenovirus serotype 26 (Ad26) has
shown promise as a candidate HIV-1 vaccine vector. Preclinical
studies in rhesus monkeys have shown that replication-incompe-
tent Ad26 vector-based vaccine regimens can provide partial
protection against both simian immunodeficiency virus 251
(SIVmac251) and simian-human immunodeficiency virus (SHIV)-
SF162P3 challenges (1, 2). In addition, a replication-incompetent
Ad26 vector expressing the HIV-1 envelope (Env) gene proved
safe and immunogenic in phase 1 clinical trials (3–5). A related
strategy is to use live replicating vaccine vectors that express
HIV-1 antigens (6). We therefore explored the potential utility of
a replicating Ad26 vector as a candidate HIV-1 vaccine.
Mosaic HIV-1 Env immunogens (e.g., Mos1Env) were devel-
oped to begin to address the challenge ofHIV-1 sequence diversity
(7). Mosaic immunogens are bioinformatically engineered to op-
timize coverage of global HIV-1 sequence diversity (7–12). Mo-
saicHIV-1 immunogens have shown increased breadth and depth
of cellular immune responses compared with those of consensus
or natural sequences in monkeys (7, 11). It has also been shown
that adenovirus and poxvirus vectors expressing mosaic Gag,
Pol, and Env sequences afforded a significant reduction in the
per-exposure risk of SHIV-SF162P3 acquisition in rhesus mon-
keys (2). Moreover, mosaic Env antigens induced greater binding
and neutralizing antibodies than those of natural sequence anti-
gens (7).
A replication-competent Ad vector might provide several the-
oretical advantages over a replication-incompetent vector, in-
cluding the potential for improved cellular and humoral immune
responses and augmented mucosal effector responses. In this
study, we describe the preclinical development of a replication-
competent Ad26 (rcAd26) vaccine vector that expresses mosaic
HIV-1 Env.We assessed the impact of vectorization on the growth
kinetics of rcAd26 in vitro. Specifically, we evaluated whether the
deletion of E3 and/or E4 and insertion of theHIV-1 Env transgene
would result in vector attenuation. In addition, we compared the
replicative capacity of rcAd26 to an rcAd4 vector that has already
been shown to be safe in phase 1 clinical trials (13–15) to facilitate
first-in-human clinical testing of the rcAd26 vector.
MATERIALS AND METHODS
Vector construction. The rcAd26 vector systemwas produced by cloning
the adenovirus E1 region from wild-type Ad26 into pAdApt26, the adap-
tor plasmid that we had previously made to produce replication-incom-
petent Ad26 vectors (16). The adaptor plasmid for the rcAd vector system,
termed pAdApt26.E1atg, has a final structure that includes the left in-
verted terminal repeat of Ad26 nucleotides 1 to 471 flanked by the trans-
gene cassette under the control of a cytomegalovirus (CMV) promoter
and SV40 poly(A), followed by the Ad26 nucleotides 463 to 5913
cloned into a pBR322 backbone. This adapter plasmid contains suffi-
cient Ad26 sequences to allow for homologous recombination with an
Ad26-derived cosmid after cotransfection. The Ad5 E4orf6 sequences
in the pWe.Ad26.dE3.5orf6 cosmid (16) were also replaced with the
Ad26 E4orf6 sequences from wild-type Ad26. To accommodate large
transgene sequences, the E4orf1 to E4orf4 regions (nucleotides 33261
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to 34683), in addition to E3, were deleted. All plasmids and cosmids
were screened by restriction enzyme analysis and complete sequencing.
The rcAd26.dE3.dE4.Mos1Env vector was also fully sequenced. The
rcAd4.H5 (Ad4-H5-Vtn) vector and Ad4-wild type (WT) were obtained
from PaxVax (San Diego, CA).
Vector production. Vectors were produced as described previously
(16, 17). Briefly, Ad26-based vectors were produced by homologous re-
combination after cotransfection of an Ad26 adaptor plasmid that ex-
pressed either no transgene (empty) or HIV-1 Mos1Env, along with the
appropriate Ad26 cosmid with either E3 or E3/E4 deleted. The plasmids
and cosmids were linearized prior to transfection of Per55K cells with
Lipofectamine 2000 (Invitrogen) in T25 flasks. After 48 h, cells were pas-
saged in T75 flasks and monitored for virus cytopathic effect. The vectors
were plaque purified, and the plaques were screened for transgene se-
quence and expression and by PCR to confirm the hexon sequences. Vec-
tors were then produced in 24 triple-layer flasks, purified by a cesium
chloride gradient ultracentrifugation, and dialyzed into phosphate-buff-
ered saline (PBS) containing 5% sucrose. Purified Ad26 vectors were
stored at 80°C. Virus particle (vp) titers were determined by spectro-
photometry, and specific infectivity was assessed by PFU assays.
In vitro replicative capacity. The growth of a panel of rcAd26 vectors
was compared to that of wild-type Ad26 in the following cell lines: A549
(human epithelial lung carcinoma cell line, ATCC CCL-185; ATCC, Ma-
nassas, VA), HuTu80 (human duodenum adenocarcinoma cell line;
ATCC HTB-40), Per55K (human cell line that complements the Ad E1
region), and LLC-MK2 (rhesus kidney cell line, ATCC CCL-7). Each cell
line was grown in Dulbecco’s modified Eagle medium (Gibco, NY, USA)
supplemented with 10% fetal bovine serum (Seradigm, UT, USA). PFU
assays were performed by infecting A549 cells that had been seeded into
6-well plates at a concentration of 8.5 105 cells per well the day before
with serial dilutions of adenovirus. The next day, an agar overlay was
added, and plaques were counted at days 7 and 14 postinfection. All serial
dilutions were done in duplicate.
The kinetics of virus replicationwas also assessed in a semiquantitative
cytopathic effect (CPE) assay: the day before infection, cells were seeded
into 6-well plates at a concentration of 8.5 105 cells per well. The next
day, cells were infected with each adenovirus vector at multiplicities of
infection (MOIs) of 1,000, 333, 100, 33, 10, and 0 vp per cell. The number
of virus particles per milliliter of the starting material was determined by
the optical density (OD), and the virus particle-to-PFU ratios for all of the
vectors were similar (21 to 41 vp/PFU). The cultures were thenmonitored
and scored daily for percent CPE for 6 days postinfection. Each vector and
cell line combination was tested in 3 replicate experiments.
To confirm the infectivity of the viruses with two subsequent passages,
viral lysates were harvested from each primary culture at full CPE by
harvesting both the cells and supernatant by pipette and freezing at20°C
until further testing. Subsequent reinfections were performed by thawing
and then clarifying each lysate by centrifugation. To reinfect the cells, 100
l of each lysate was added to cells that had been seeded the day before at
8.5 105 cell per well into a 6-well plate. Cultures were then monitored
and scored daily for percent CPE for 6 days postinfection and infected cell
lysates harvested the day of full CPE.
Immunogenicity in mice. To assess the immunogenicity of the clini-
cal candidate rcAd26.Mos1Env vector, BALB/c mice (n 4) were immu-
nized intramuscularly or intranasally with 1  1010 vp replication-com-
petent rcAd26.dE3.dE4.Mos1Env or replication-incompetent (ri) vector
ri(E1).Ad26.dE3.Mos1Env at day 0. Serumwas obtained at day 0 preim-
munization and weekly at days 7, 14, 21, and 28 postimmunization. Env-
specific antibody titers in these sera were assessed by enzyme-linked im-
munosorbent assay (ELISA) to HIV-1 Mos1Env protein developed with
SureBlue 3,3=,5,5=-tetramethylbenzidine (TMB) Microwell peroxidase
substrate (KPL). Log10 values were plotted using GraphPad Prism 6. Env-
specific T lymphocyte responses were assessed by gamma interferon
(IFN-) enzyme-linked immunosorbent spot assay (ELISPOT), as de-
scribed previously (18, 19). Spleens were harvested at day 28 postimmu-
nization, and splenocytes were isolated and stimulated with Mos1Env 1,
Mos1Env 2, potential T cell epitope (PTE) Env 1, PTE Env 2, and PTE Env
3 peptide pools (20).
RESULTS
Construction of the rcAd26 vector system.A replication-compe-
tent version of Ad26 (rcAd26) was constructed by adding the
Ad26 E1 region 5= of the transgene cassette in the replication-
incompetent version of our Ad26 vector (16). In addition, rcAd26
has the E3 region deleted and the Ad5 E4orf6 region replaced by
the Ad26 E4orf6 to make the vector fully replication competent.
The vector expressed themosaicHIV-1Env immunogen (Mos1Env)
antigen. To ensure adequate coding capacity, we also deleted the
E4orf1 to E4orf4 regions from rcAd26, resulting in our clinical
candidate vector rcAd26.dE3.dE4.Mos1Env (Fig. 1A).
We first confirmed that rcAd26 could replicate in A549 cells,
which do not complement the Ad E1 region. The growth kinetics
of rcAd26.empty (with no transgene) was compared to that of
wild-type Ad26 and the replication-incompetent Ad26 vector
ri(E1)Ad26.dE3.empty. In this experiment, wild-type Ad26 and
rcAd26.dE3.empty grew efficiently in A549 cells infected with an
MOI of 1,000 or 100, whereas the replication-incompetent Ad26
vector did not. As expected, all vectors grew well in Per55K cells,
which complements Ad E1 (Fig. 1B). Replication of the rcAd26
vectors was species specific, as these vectors did not replicate in the
rhesus monkey cell line MK2 (Fig. 1C), whereas a replication-
competent simian Ad vector derived from rhesus monkeys (21)
replicated well in MK-2 cells. The rcAd26 vectors also did not
grow in mouse cell lines (data not shown).
Replication-competent rcAd26 vectors are attenuated com-
pared to wild-type Ad26. The infectivity of a panel of rcAd26
vectors (Table 1) was assessed in human cell lines to determine if
the deletion of E3 and E4 and the insertion of theMos1Env trans-
gene impacted the viral replicative capacity in vitro. The rcAd26
vectors used in this study included wild-type Ad26, the clinical
candidate rcAd26.dE3.dE4.Mos1Env, and other versions of the
vector that had E3 and/or E4 deleted and were with or without the
Mos1Env transgene. We utilized a quantitative PFU assay to eval-
uate virus titers, and we also evaluated virus growth kinetics uti-
lizing semiquantitative CPE monitoring.
We first tested the replication capacity of these vectors by in-
fectingHuTu80 (duodenal) or A549 (human epithelial) cells at an
MOI of 1,000 vp/cell and harvesting cell lysates at full CPE. The
viral titer in each lysate was quantitated by PFU assays in duplicate
(Fig. 2). When the vectors were grown in HuTu80 cells, the
rcAd26.dE3.empty vector had a mean PFU titer that was 1.3
logs lower than that of wild-type Ad26. However, with E3 and
E4 deleted, the rcAd26.dE3.dE4.empty vector had a mean
PFU titer 2.2 logs lower than that of wild-type Ad26. With the
addition of the Env transgene, the mean PFU titer was 3.0 logs
less than that of wild-type Ad26 when only E3 was deleted
(rcAd26.dE3.Mos1Env).With both E3 and E4 deleted, the clinical
candidate vector rcAd26.dE3.dE4.Mos1Env demonstrated the
most pronounced attenuation, with a mean PFU titer 4.4 logs
lower than that of wild-type Ad26 (Fig. 2; P  0.05 for PFU
titers of all recombinant vectors compared with wild-type
Ad26). An attenuated replicative capacity was similarly ob-
served in A549 cells. The rcAd26.dE3.empty vector had a PFU
titer similar to that of wild-type Ad26.With E3 and E4 deleted, the
rcAd26.dE3.dE4.emptyvectorhadaPFUtiter1.9 logs lower than that
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of wild-type Ad26. When the Mos1Env transgene was added, the
rcAd26.dE3.Mos1Env vector had a PFU titer 2.1 logs lower than that
of wild-type Ad26, and the rcAd26.dE3.dE4.Mos1Env vector had a
PFU titer 2.7 logs lower than that of wild-type Ad26. These effects
were not due to differential specific infectivities of the different
vectors, since the virus particle-to-PFU ratios for all the recombi-
nant vectors were similar (23 to 41 vp/PFU), which would not
account for the 2.7- to 4.4-log difference in replicative capacity of
the clinical candidate rcAd26.dE3.dE4.Mos1Env vector compared
with the wild-type Ad26 vector.
In addition to the quantitative PFU assay, we also compiled
semiquantitative vector growth kinetics in A549, HuTu80, and
Per55K cells, expressed as percent CPE over time. All rcAd26 vec-
tors exhibited slower growth kinetics than that of wild-type Ad26
in the A549 (human epithelial) (Fig. 3A) andHuTu80 (duodenal)
(Fig. 3B) cell lines. Consistent with the quantitative PFU assay, the
FIG 1 The rcAd26 vaccine vector replicates in human cell lines but not in a rhesus cell line. (A) Schematic of the construction of the replication-competent Ad26
vaccine vector fromwild-type Ad26. lITR, left inverted terminal repeat; rITR, right inverted terminal repeat. (B) Vector replicationwas evaluated in vitro in A549
(human; does not complement E1) and Per55K (human; complements E1) cell lines. Cells were infected atMOIs of 1,000, 100, and 10, and they weremonitored
daily for CPE over 6 days. The rcAd26 vector growth was compared to that of the replication-incompetent vector ri(E1).Ad26.dE3 and wild-type Ad26. (C)
Vector replication was evaluated in vitro in the MK-2 cell line (rhesus monkey kidney). Cells were infected at MOIs of 1,000, 333, and 100 vp/cell, and they were
monitored daily for CPE over 6 days. Growth of a replication-competent simian adenovirus vector was utilized as a positive control. Error bars indicate standard
errors of the means (SEM).
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semiquantitative growth kinetics suggested stepwise reductions
with E3 deletion, E4 deletion, andHIV-1 Env transgene insertion.
The clinical candidate vector rcAd26.dE3.dE4.Mos1Env demon-
strated substantial reductions in growth kinetics compared with
that of wild-type Ad26 in both cell lines. As expected, the replica-
tion-incompetent Ad26 vectors did not replicate in either the
A549 or HuTu80 cell line. As a control, we observed that all vec-
tors replicated well in E1-complementing Per55K cells (Fig. 3C).
To verify that the CPE observed in this assay system indicated
that the rcAd26 was an infectious virus, we harvested cultures at
full CPE and performed two additional passages of the virus in
either A549 or HuTu80 cells. One hundred microliters of cell ly-
sate harvested at full CPE from the cultures infected with either
1,000 vp/cell or 333 vp/cell of each vector was used for reinfection.
Lysates harvested from the first reinfection at full CPE were then
used for the second reinfection. All rcAd26 vectors replicated
through 2 passages in both A549 andHuTu80 cell lines, indicating
that the CPE observed reflected infectious virus and not nonspe-
cific cell toxicity (Fig. 4A and B).
rcAd26.dE3.dE4.Mos1Env is more attenuated than rcAd4.H5.
We next compared the in vitro growth kinetics of our clinical candi-
date vector, rcAd26.dE3.dE4.Mos1Env, to that of rcAd4.H5 (Ad4-
H5-Vtn; PaxVax),which is anAd4-based vector expressing influenza
H5 andwas previously proven in a phase 1 clinical trial to be safe and
immunogenic (13–15). The rcAd26.dE3.dE4.Mos1Env vaccine
showedmarkedly reduced replicative capacity compared to that of
rcAd4.H5 in both A549 cells (Fig. 5A) andHuTu80 cells (Fig. 5B).
As expected, all vectors grew well in Per55K cells (Fig. 5C).
rcAd26.dE3.dE4.Mos1Env induces humoral and cellular im-
munity inmice. To verify that Mos1Env was immunogenic when
expressed from the clinical candidate rcAd26.dE3.dE4.Mos1Env,
BALB/c mice (n  4) were immunized either intramuscularly or
intranasally with a single administration of 1  1010 vp of the
clinical candidate rcAd26.dE3.dE4.Mos1Env vector or replica-
tion-incompetent vector ri(E1).Ad26.dE3.Mos1Env. However,
rcAd26 vectors do not replicate in mice (data not shown); thus,
this experiment was unable to assess the impact of vector replica-
tion on immune responses. The antibody titers in sera from day 0
preimmunization and day 28 postimmunization were assessed by
ELISA. As shown in Fig. 6A, rcAd26.dE3.dE4.Mos1Env in-
duced binding antibodies to MosI Env glycoprotein 140
(gp140) antigens. The titers were comparable to those induced
by immunization with ri(E1).Ad26.dE3.Mos1Env, a replica-
tion-incompetent Ad26 vector expressingMos1Env, which was
previously evaluated (2, 7). To assess cellular immune responses,
splenocytes were assessed by IFN- ELISPOT assays on day 28
postimmunization. Cellular immune responses generated by
rcAd26.dE3.dE4.Mos1Envwere comparable to those generated by
the replication-incompetent vector ri(E1).Ad26.dE3.Mos1Env
when stimulated with Mos1Env and PTE Env peptide pools,
as shown in Fig. 6B. These data demonstrate that the rcAd26.
dE3.dE4.HIVMos1Env vector is immunogenic inmice, although the
potential benefits of vector replication were not assessed.
DISCUSSION
We have developed a replication-competent Ad26 vector plat-
form for clinical evaluation. All of the rcAd26 vectors were atten-
uated compared with wild-type Ad26 in both the A549 and
HuTu80 cell lines. The attenuation was most pronounced when
both E3 and E4 were deleted and the HIV-1 Env transgene was
expressed. Using quantitative PFU assays, the clinical candidate
vector rcAd26.dE3.dE4.Mos1Env showed a 4.4-log reduction
in replicative capacity compared with that of wild-type Ad26 in
the duodenal cell line HuTu80. In addition, rcAd26.Mos1Env
exhibited slower growth kinetics than that of rcAd4.H5, which
has already been proven safe in a phase 1 clinical trial. The
rcAd26.dE3.dE4.Mos1Env vector was immunogenic in mice, al-
though the impact of vector replication could not be assessed,
since rcAd26 does not replicate in mice. This vector is currently
being evaluated in a phase 1 clinical trial (rcAd001/IAVI R001).
The deletion of E3 and E4 and the addition of the Mos1Env
transgene all appeared to contribute to vector attenuation in a
stepwise fashion, suggesting at least two mechanisms that may
contribute to the attenuation of these vectors. First, there may be
a requirement for E3 or E4 for optimal Ad26 replication, although
this requirement was not evident with Ad5 vectors (22). Second,
expression of the HIV-1 Env transgene likely reduces replication
efficiency, as it requires substantial cellular metabolic resources.
A replication-incompetent Ad26 vector expressing a prototype
HIV-1 EnvA antigen has already been tested in humans in three
phase 1 clinical studies, and to date, it has been shown to be safe
and immunogenic (3–5). However, replication-competent Ad26
has not been evaluated in humans. Ad26 is a biologically different
less inflammatory vector than Ad5 and is different from Ad5 in
terms of receptor usage, in vivo tropism, interactions with den-
TABLE 1 Panel of vectors used for in vitro infectivity comparison
Vector
Replication
competent
E3
deleted E4 deleteda Transgene
rcAd26.dE3.dE4.Mos1Envb Yes Yes Yes HIV-1 Mos1Env
rcAd26.dE3.Mos1Env Yes Yes No HIV-1 Mos1Env
rcAd26.dE3.dE4.empty Yes Yes Yes No
rcAd26.dE3.empty Yes Yes No No
Ad26.WT Yes No No No
ri(E1)Ad26.dE3.empty No Yes No No
ri(E1)Ad26.dE3.Mos1Env No Yes No HIV-1 Mos1Env
Ad4.WT (PaxVax) Yes No No No
rcAd4.H5 (PaxVax) Yes Partial No Influenza H5
a E4orf1 to E4orf4 deleted.
b Clinical candidate rcAd26.Mos1Env.
FIG 2 Titers generated by the panel of rcAd26 vectors (Table 1) were com-
pared in lysates from cells infected with each vector at anMOI of 1,000 vp/cell
and harvested at full CPE. Lysates from either infected HuTu80 cells (human
duodenum; does not complement E1) or A549 cells (human; does not com-
plement E1) were compared by performing the plaque assay in duplicate in
A549 cells (human; does not complement E1). Data are shown as means with
standard deviations.
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FIG 3 Growth of rcAd26.dE3.dE4.Mos1Env is attenuated in vitro compared to that of wild-type Ad26. The growth kinetics of a panel of Ad26-based vectors
(Table 1) were compared in vitro. Cell lines were infected with vectors or wild-type virus at anMOI of 1,000, 333, 100, 33, or 10 vp/cell, and they weremonitored
daily for CPE over 6 days. Vector growth was evaluated in A549 cells (human; does not complement E1) (A), HuTu80 cells (human duodenum; does not
complement E1) (B), and Per55K cells (human; complements E1) (C). Error bars indicate standard errors of the means (SEM).
Maxﬁeld et al.
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dritic cells, innate immune profiles, and adaptive immune pheno-
types (16, 17, 23–29).
It remains unclear how to increase the potency and durability
of HIV-1-specific immunity. One strategy is to use live replicating
vectors (6). Live attenuated viral vaccines have been shown to be
effective in both humans and animals (6) and include some of the
most widely used licensed vaccines for measles-mumps-rubella
viruses, yellow fever virus, varicella virus, influenza virus, and ro-
tavirus (30). Attenuated simian immunodeficiency virus (SIV)
has also shown robust protection against challenge with patho-
genic SIV in rhesus monkeys (31–34), but live attenuated HIV-1
has not been pursued as a vaccine concept due to safety concerns
(35). Recent studies have also shown that immunization with a
replicating cytomegalovirus vector expressing SIV antigens led to
immune control and possible clearance of highly pathogenic SIV
infection in approximately half of rhesus monkeys (36). These
data suggest the potential utility of replicating vectors expressing
HIV-1 antigens.
The protective efficacy of replication-competent viral vectors
may theoretically be superior to that of replication-incompetent
viral vectors, as theymight elicit different or more comprehensive
innate, cellular, and humoral immune responses. In addition, rep-
licating vectors may lead to enhanced mucosal immunity, al-
though these hypotheses remain to be tested. These features are
relevant to HIV-1 vaccine design, as HIV-1 exposure occurs at
mucosal sites, and early HIV-1 replication targets mucosal CD4
T cells within gut-associated lymphoid tissue (GALT) (37). It is
likely that protective immunity will require antibody responses
and host CD8 T cells that can limit HIV-1 replication (38).
Live attenuated adenovirus vaccines have a proven track re-
cord of safety and efficacy for the prevention of Ad4 and Ad7
respiratory illness (39–41). These vaccines have been adminis-
FIG 4 Replication of rcAd26 vectors is observed through two cell passages. The replication kinetics of the panel of rcAd26 vectors (Table 1) were compared
through two passages in cell culture. Cell lysate was harvested from cultures at full CPE after infection at anMOI of 1,000 or 333 vp/cell. One hundredmicroliters
of this lysate was used to infect either A549 (A) orHuTu80 (B) cells, depending on the original cell line used. The reinfected culture was harvested at full CPE, and
100 l of these lysates was used to infect either A549 (A) or HuTu80 (B) cells with a second passage of vector. CPE was monitored for 6 days.
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FIG 5 rcAd26.dE3.dE4.Mos1Env is attenuated in vitro compared to rcAd4.H5. The growth kinetics of a panel of Ad26-based and Ad4-based vectors (Table 1)
were compared in vitro. Cell lines were infected with vectors or wild-type virus at anMOI of 1,000, 333, 100, 33, or 10 vp/cell, and they were monitored daily for
CPE over 6 days. Vector growthwas evaluated in A549 cells (human; does not complement E1) (A), HuTu80 cells (human duodenum; does not complement E1)
(B), and Per55K cells (human; complements E1) (C). The growth of rcAd26.dE3.dE4.Mos1Env and rcAd4.H5 is shown. Error bars indicate standard errors of the
means (SEM).
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tered safely to 	10 million people over the span of nearly 60
years (41) and effectively prevent adenovirus disease outbreaks
in military recruits (40). Oral live recombinant Ad4 (Ad4-H5-
Vtn, or rcAd4.H5) vectors for influenza were also recently
shown to be safe and immunogenic in an early phase clinical
trial (14, 15). In addition, rcAd4 expressing HIV-1 envelope
1086 cladeC is being evaluated (42). The lower replicative capacity
of rcAd26.dE3.dE4.Mos1Env compared with that of rcAd4.H5 in
vitro (Fig. 5) will facilitate, from a safety and regulatory perspec-
tive, the clinical development of rcAd26.dE3.dE4.Mos1Env,
which is currently in a phase 1 clinical trial.
In this study, we describe the preclinical development of a rep-
lication-competent Ad26-based vaccine vector that expresses a
mosaic HIV-1 Env immunogen. The rcAd26.dE3.dE4.Mos1Env
vaccine candidate was found to be substantially attenuated com-
pared to wild-type Ad26 as a result of vectorization, which has
important clinical, regulatory, and immunologic implications.
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